Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 +0.64%80 Earnings Yield (Joel Greenblatt) % is 9.84% as of Jun. 2026, which is 59% above its 10-year median of 6.18. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$29.98 (Fairly Valued). The stock has 4 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Apex Biotechnology ranks better than 85.58% on this metric.
Apex Biotechnology's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,259 Mil.
Apex Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$222 Mil. Apex Biotechnology's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 9.84%.
The historical rank and industry rank for Apex Biotechnology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TPE:1733'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.35 Med: 6.18 Max: 10.16
Current: 9.03
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Apex Biotechnology was 10.16%. The lowest was -2.35%. And the median was 6.18%.
TPE:1733's Earnings Yield (Joel Greenblatt) % is ranked better than 85.58% of 846
companies
in the Medical Devices & Instruments industry
Industry Median: 0.985
vs TPE:1733: 9.03
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Apex Biotechnology's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 2.97%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Apex Biotechnology Earnings Yield (Joel Greenblatt) % Related Terms
Apex Biotechnology Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Apex Biotechnology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apex Biotechnology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Apex Biotechnologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Apex Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$222 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 9.84% mean?
Apex Biotechnology (TPE:1733) has a Earnings Yield (Joel Greenblatt) % of 9.84% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Apex Biotechnology and its competitors. This is 59% above median its historical median of 6.18. According to the industry distribution chart, Apex Biotechnology ranks #122 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 14.4%.
Is Apex Biotechnology's Earnings Yield (Joel Greenblatt) % too high?
Apex Biotechnology's current Earnings Yield (Joel Greenblatt) % of 9.84% is 59% above median its 10-year median of 6.18. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.99. Apex Biotechnology's value of 9.84% is 899% above this industry median. Based on the distribution chart, Apex Biotechnology ranks #122 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Medical Devices & Instruments industry distribution chart, Apex Biotechnology ranks #122 out of 846 companies for Earnings Yield (Joel Greenblatt) %. This places Apex Biotechnology in the top 14% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 0.99. Apex Biotechnology's value of 9.84% is 899% above this benchmark. While the company's 10-year median is 6.18 vs. the industry median of 0.99, Apex Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.99, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Earnings Yield (Joel Greenblatt) % of 9.84% is 899% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Apex Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Earnings Yield (Joel Greenblatt) % is 9.84%, which is 59% above median its own 10-year median of 6.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.98, compared to a current price of NT$31.35 — trading 4.6% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 9.84%, which is 59% above median its 10-year median of 6.18 and 899% above the Medical Devices & Instruments industry median of 0.99. Apex Biotechnology's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Earnings Yield (Joel Greenblatt) % is 9.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$31.35 is trading 4.6% above its estimated GF Value™ of NT$29.98.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Earnings Yield (Joel Greenblatt) %: 9.84% (59% above median its 10-year median of 6.18)
GF Value™: NT$29.98 vs. price of NT$31.35 (4.6% above fair value)
Industry Position: 899% above the Medical Devices & Instruments median (#122 of 846)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
